Protein-protein interactions (PPIs) play a fundamental role in all life events and cellular activities. PPIs can form a large and complex network, with more than 500,000 PPI dysregulations associated with pathological events, and the resolution of such dysregulations has been recognized as a promising therapeutic target for the treatment of many diseases, including ischemic stroke. Therefore, natural or synthetic peptides capable of interfering with PPIs (also known as interfering peptides) are receiving increasing attention. Due to their physicochemical properties, interfering peptides appear to be better suited than small molecules to interfere with the large surfaces involved in PPIs. In addition, advances in peptide administration, stability, delivery, and safety have stimulated interest in peptide drug development.
Fig. 1. Effect of synthetic inhibitors on GABAB receptor recirculation. (Dergunova et al., 2023)
Ace Therapeutic offers customized interfering peptide development services to help clients develop drugs for stroke. By identifying and characterizing key PPIs involved in stroke pathology, we help clients develop drugs that interfere with PPIs in ischemic stroke.
Our highly skilled neuropeptide development team can utilize molecular dynamics simulations and advanced screening techniques to achieve efficient and rational design of interfering peptide. We aim to accelerate the process of stroke drug development programs by discovering more low-toxicity interfering peptides with neuroprotective activity and inhibiting the excitatory neuronal death through rational structural design.
We provide in silico, physicochemical, and biological strategies for the design and optimization of interfering peptides.
We use rigorous in vitro and in vivo assays to validate the efficacy and safety of interfering peptides.
Ace Therapeutics is your trusted partner, provides comprehensive services in the development of interfering peptides for the treatment of stroke. If you are interested in our services, please do not hesitate to contact us!
We are committed to accelerating progress in stroke research and drug development.